Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 8, 2000, Pages 461-467

  Cividalli, A ^a   Mauro, F ^a   Livdi, E ^b   Ceciarelli, F ^a   Altavista, P ^a   Cruciani, G ^b   Tirindelli Danesi, D ^a  

^a ENEA   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

Gemcitabin; Mouse mammary carcinoma; Paclitaxel

Indexed keywords

GEMCITABINE; PACLITAXEL;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; PACLITAXEL; STATISTICS, NONPARAMETRIC;

EID: 85047696677     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050014     Document Type: Article

References (35)

1. Abrams JS, Vena DA, Baltz J, Adams J, Montello M, Christian M, Onetto N, Desmond-Helmann S, Canetta R, Friedman MA, Arbuck SG (1995) Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13: 2056-2065
2. Boven E, Schipper H, Erkelens CAM, Hatty SA, Pinedo HM (1993) The influence of the schedule and the dose of Gemcitabine on the anti-tumor efficacy in experimental human cancer. Br J Cancer 68: 52-56
3. Braakhuis BJM, van Dongen GAMS, Vermorken JB, Snow GB (1991) Preclinical in vivo activity of 2′, 2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 51: 211-214
4. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G, Peters GJ (1995) Schedule-dependent antitumor effect of Gemcitabine in in vivo model systems. Sem Oncol 22 (S11): 42-46
5. Bunn Jr PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 5: 1087-1100
6. Carmichael J (1998) The role of Gemcitabine in the treatment of other tumors. Br J Cancer 78 (S3): 21-25
7. Cividalli A, Arcangeli G, Cruciani G, Livdi E, Cordelli E, Tirindelli Danesi D (1998a) Enhancement of radiation response by Paclitaxel in mice according to different treatment schedules. Int J Radiat Oncol Biol Phys 40: 1163-1170
8. Cividalli A, Cruciani G, Livdi E, Cordelli E, Eletti B, Tirindelli Danesi D (1998b) Greater antitumor efficacy of Paclitaxel administered before epirubicin in a mouse mammary carcinoma. J Cancer Res Clin Oncol 124: 236-244
9. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699
10. Hainsworth JD, Burris III HA, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin Jr DC, Smith SW, Greco FA (1999) Phase I/II trial of Paclitaxel by 1-hour infusion carboplatin, and Gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer 85: 1269-1276
11. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1992) Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52: 533-539
12. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of Gemcitabine (2′, 2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422
13. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
14. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 75: 869-877
15. Kaye SB (1998) New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer 78 (S3): 1-7
16. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of Paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68: 1104-1109
17. Long BH, Fairchild CR (1994) Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 54: 4355-4361
18. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32: 235-242
19. Markman M (1996) Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn. J Cancer Res Clin Oncol 122: 71-73
20. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ (1995) Role of reoxygenation in induction of enhancement of tumor radioresponse by Paclitaxel. Cancer Res 55: 3564-3568
21. Miwa M, Eda H, Ura M, Ouchi KF, Keith DD, Foley LH, Ishitsuka H (1998) High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2′-deoxycytidine antimetabolite, 2′-deoxy-2′-methylidenecytidine. Clinical Cancer Res 4: 493-497
22. Overgaard J (1980) Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 6: 1507-1517
23. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin in Oncol 23 (suppl. 10): 3-15
24. Riccardi A, Servidei T, Tornesello A, Puggioni P, Mastrangelo S, Rumi C, Riccardi R (1995) Cytotoxicity of Paclitaxel and Docetaxel in human neuroblastoma cell lines. Eur J Cancer 31 A: 494-499
25. Rose WC (1992) Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3: 311-321
26. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19: 646-662
27. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ (1994) Schedule dependence of sensitivity to 2′, 2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol 48: 1327-1339
28. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565
29. Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB (1993) Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5: 223-228
30. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L (1995) Phase II trial of Paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13: 2575-2581
31. Steward WP (1998) Combination studies with Gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer 78 (S3): 15-19
32. Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB (1998) Interaction of Gemcitabine with Paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 12: 825-833
33. UKCCCR, United Kingdom Co-ordinating Comittee on Cancer Research Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition) (1998). Br J Cancer 77: 1-10
34. Von Hoff DD, Goodwin AL, Garcia L, The San Antonio Drug Development Team (1998) Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. Br J Cancer 78 (S3): 9-13
35. Zoll W, Ricotti L, Barzanti F, Dal Susino M, Frassineti GL, Milandri C, Casadei Giunchi D, Amadori D (1999) Schedule-dependent interaction of doxorubicin, Paclitaxel, and Gemcitabine in human breast cancer cell lines. Int J Cancer 80: 413-416